H. Lundbeck A/S has released six-month data from the ongoing twelve-month INFUSE study, evaluating the real-world effectiveness of Vyepti (eptinezumab) in adults with migraine who had previously not responded to at least one preventive anti-CGRP therapy. The findings, presented at the 2026 Headache Cooperative of the Pacific Annual Conference in California, show meaningful improvements across multiple patient-reported measures in individuals switching to intravenous eptinezumab despite high baseline disease burden. Migraine remains one of the most common neurological disorders globally, and many patients continue to experience significant symptoms even with existing preventive treatments due to limited efficacy or tolerability issues. Previous evidence suggests that switching between subcutaneous anti-CGRP therapies provides only modest improvement, while data on switching to intravenous eptinezumab in real-world settings has been limited.

Health Technology Insights: Mary Free Bed at Home Named Among Best Home Health Agencies 2026

Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck, said that the new data confirms eptinezumab’s potential to improve migraine outcomes not only in controlled clinical trials but also in routine practice. He noted that the INFUSE study shows consistent reductions in migraine frequency and improvements in daily functioning for patients who had not seen sufficient benefit from previous preventive anti-CGRP treatments.

Health Technology Insights: Lucent Health Appoints Aadam Hussain as CEO After Rodewald Retires

The INFUSE study is a prospective observational study in which adults with migraine were recruited through two Vyepti Infusion Network partners in the United States. Participants had previously failed at least one preventive anti-CGRP therapy due to lack of efficacy or side effects. The current analysis includes 111 participants who completed six months of treatment with eptinezumab. Safety information was collected through standard reporting channels.

After two infusions, 75.7 percent of participants reported improvements in migraine status, with 44.1 percent describing themselves as much or very much improved. Participants experienced an average reduction of 6.8 monthly headache days from a baseline of 20, with 44.1 percent achieving at least a 50 percent reduction and 26.1 percent seeing a reduction greater than 75 percent. Additionally, participants reported an average of 6.3 more “good days” per month compared with baseline, reflecting improvements in daily functioning and quality of life.

Eptinezumab has shown a favorable tolerability profile in clinical trials, with over 2,000 adults receiving at least one dose. The most common side effects reported in the PROMISE-1 and PROMISE-2 studies were nasopharyngitis and hypersensitivity. The INFUSE study is part of Lundbeck’s broader commitment to generating real-world evidence in migraine and advancing care for this complex and progressive neurological disease that affects millions worldwide. Through its research and development, Lundbeck aims to provide innovative therapies and support healthcare professionals in delivering patient-centered care that reduces migraine burden.

Migraine is a chronic and disabling condition characterized by recurrent severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. Beyond the physical pain, migraine has significant social and economic impacts, affecting relationships, leisure, household productivity, and work performance. It is among the leading causes of disability globally, particularly for people under 50. Without effective preventive management, repeated migraine attacks can lead to increased use of acute medications, decreased effectiveness of treatments, and progression toward chronic migraine, creating a cycle of worsening symptoms and reduced quality of life.

Health Technology Insights: Prescryptive and Ilant Health Expand Employer GLP-1 Access

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com